GlassScriptPhysician profile
Erin Farrell
NPI 1770773335
$4,931.33
in general payments reported to CMS, 2019-2025
23 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $50.97 · 2021: $834 · 2022: $1,244 · 2023: $938 · 2024: $588 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $959.91 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $471.83 | 2022-2025 | Miebo, Xiidra, Lotemax Sm |
| Sun Pharmaceutical Industries INC. | $463.88 | 2020-2023 | Cequa |
| Oyster Point Pharma, INC. | $450.42 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $376.75 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $316.27 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $313.62 | 2021-2025 | Acthar |
| Alcon Vision LLC | $239.73 | 2021-2024 | Clareon, Rocklatan |
| Tarsus Pharmaceuticals, INC. | $202.96 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $182.95 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $163.41 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $131.02 | 2022-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $127.62 | 2019-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2021 | |
| Rxsight INC | $104.53 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $86.46 | 2023 | Izervay |
| Eyevance Pharmaceuticals LLC | $64.63 | 2022-2023 | Flarex |
| Thea Pharma INC. | $33.79 | 2022-2025 | Iyuzeh |
| Boston Scientific Corporation | $31.24 | 2023 | Advantage System |
| Harrow Eye, LLC | $25.40 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $24.78 | 2021 | |
| Biotissue Holdings INC. | $20.60 | 2025 | |
| Rayner Intraocular Lenses Limited | $14.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.